Literature DB >> 21358274

Mesenchymal stem cells expressing GD2 and CD271 correlate with breast cancer-initiating cells in bone marrow.

Ugo De Giorgi1, Evan N Cohen, Hui Gao, Michal Mego, Bang-Ning Lee, Ashutosh Lodhi, Massimo Cristofanilli, Anthony Lucci, James M Reuben.   

Abstract

PURPOSE: The bone marrow microenvironment is considered a critical component in the dissemination and fate of cancer cells in the metastatic process. We explored the possible correlation between bone marrow mesenchymal stem cells (BM-MSC) and disseminated breast cancer-initiating cells (BCIC) in primary breast cancer patients. EXPERIMENTAL
DESIGN: Bone marrow mononuclear cells (BM-MNC) were collected at the time of primary surgery in 12 breast cancer patients. BM-MNC was immunophenotyped and BCIC was defined as epithelial cells (CD326+CD45-) with a "stem-like" phenotype (CD44+CD24low/-, ALDH activity). BM-MSC was defined as CD34-CD45-cells that co-expressed GD2, CD271, and/or CD200 within CD326-depleted BM-MNC.
RESULTS: The percentages of BCIC (Aldefluor+CD326+CD44+CD24-) correlated with the percentages of BM-MSC, either CD45-GD2+CD200+CD271+ (Kedall's tau = 0.684, p = 0.004) or CD45-GD2+CD271+ in the bone marrow (Kedall's tau = 0.464, p = 0.042).
CONCLUSIONS: There was a positive correlation between mesenchymal stem cells expressing GD2 and CD271 and breast cancer-initiating cells in BM of patients with primary breast cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21358274      PMCID: PMC3230296          DOI: 10.4161/cbt.11.9.15178

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  20 in total

1.  Human bone marrow mesenchymal stromal cells express the neural ganglioside GD2: a novel surface marker for the identification of MSCs.

Authors:  Caridad Martinez; Ted J Hofmann; Roberta Marino; Massimo Dominici; Edwin M Horwitz
Journal:  Blood       Date:  2007-01-30       Impact factor: 22.113

2.  Specific plasma membrane protein phenotype of culture-amplified and native human bone marrow mesenchymal stem cells.

Authors:  Bruno Delorme; Jochen Ringe; Nathalie Gallay; Yves Le Vern; Dominique Kerboeuf; Christian Jorgensen; Philippe Rosset; Luc Sensebé; Pierre Layrolle; Thomas Häupl; Pierre Charbord
Journal:  Blood       Date:  2007-12-17       Impact factor: 22.113

3.  Mesenchymal stem cells in cancer: friends or foes.

Authors:  Wengeng Zhang
Journal:  Cancer Biol Ther       Date:  2008-02-25       Impact factor: 4.742

Review 4.  Human bone marrow mesenchymal stem cells in vivo.

Authors:  E Jones; D McGonagle
Journal:  Rheumatology (Oxford)       Date:  2007-11-06       Impact factor: 7.580

5.  Novel markers for the prospective isolation of human MSC.

Authors:  Hans-Jörg Bühring; Venkata Lokesh Battula; Sabrina Treml; Bernhard Schewe; Lothar Kanz; Wichard Vogel
Journal:  Ann N Y Acad Sci       Date:  2007-03-29       Impact factor: 5.691

Review 6.  Detection, clinical relevance and specific biological properties of disseminating tumour cells.

Authors:  Klaus Pantel; Ruud H Brakenhoff; Burkhard Brandt
Journal:  Nat Rev Cancer       Date:  2008-05       Impact factor: 60.716

7.  ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome.

Authors:  Christophe Ginestier; Min Hee Hur; Emmanuelle Charafe-Jauffret; Florence Monville; Julie Dutcher; Marty Brown; Jocelyne Jacquemier; Patrice Viens; Celina G Kleer; Suling Liu; Anne Schott; Dan Hayes; Daniel Birnbaum; Max S Wicha; Gabriela Dontu
Journal:  Cell Stem Cell       Date:  2007-11       Impact factor: 24.633

8.  The growth inhibitory effect of mesenchymal stem cells on tumor cells in vitro and in vivo.

Authors:  Yan-rong Lu; Yu Yuan; Xiu-jie Wang; Ling-ling Wei; You-nan Chen; Cong Cong; Sheng-fu Li; Dan Long; Wei-dong Tan; Ying-qiu Mao; Jie Zhang; You-ping Li; Jing-qiu Cheng
Journal:  Cancer Biol Ther       Date:  2007-11-14       Impact factor: 4.742

9.  Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature.

Authors:  Emmanuelle Charafe-Jauffret; Christophe Ginestier; Flora Iovino; Julien Wicinski; Nathalie Cervera; Pascal Finetti; Min-Hee Hur; Mark E Diebel; Florence Monville; Julie Dutcher; Marty Brown; Patrice Viens; Luc Xerri; François Bertucci; Giorgio Stassi; Gabriela Dontu; Daniel Birnbaum; Max S Wicha
Journal:  Cancer Res       Date:  2009-02-03       Impact factor: 12.701

10.  Mesenchymal stem cells in early entry of breast cancer into bone marrow.

Authors:  Kelly E Corcoran; Katarzyna A Trzaska; Helen Fernandes; Margarette Bryan; Marcelo Taborga; Venkatesh Srinivas; Kathryn Packman; Prem S Patel; Pranela Rameshwar
Journal:  PLoS One       Date:  2008-06-25       Impact factor: 3.240

View more
  10 in total

1.  Expression and Function of hsa-miR-6165 in Human Cell Lines and During the NT2 Cell Neural Differentiation Process.

Authors:  Maryam Hassanlou; Bahram Mohammad Soltani; Seyed Javad Mowla
Journal:  J Mol Neurosci       Date:  2017-09-27       Impact factor: 3.444

2.  Involvement of TNF-α in differential gene expression pattern of CXCR4 on human marrow-derived mesenchymal stem cells.

Authors:  Rozita Ziaei; Maryam Ayatollahi; Ramin Yaghobi; Zeinab Sahraeian; Nosratollah Zarghami
Journal:  Mol Biol Rep       Date:  2014-01-07       Impact factor: 2.316

3.  Anti-CD105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-GD2 Antibody Immunotherapy of Neuroblastoma with Activated Natural Killer Cells.

Authors:  Hong-Wei Wu; Michael A Sheard; Jemily Malvar; G Esteban Fernandez; Yves A DeClerck; Laurence Blavier; Hiroyuki Shimada; Charles P Theuer; Richard Sposto; Robert C Seeger
Journal:  Clin Cancer Res       Date:  2019-05-08       Impact factor: 12.531

Review 4.  Signaling domains of cancer-associated glycolipids.

Authors:  Koichi Furukawa; Yuhsuke Ohmi; Kazunori Hamamura; Yuji Kondo; Yuki Ohkawa; Kei Kaneko; Noboru Hashimoto; Farhana Yesmin; Robiul H Bhuiyan; Orie Tajima; Keiko Furukawa
Journal:  Glycoconj J       Date:  2022-03-22       Impact factor: 2.916

5.  Different populations and sources of human mesenchymal stem cells (MSC): A comparison of adult and neonatal tissue-derived MSC.

Authors:  Ralf Hass; Cornelia Kasper; Stefanie Böhm; Roland Jacobs
Journal:  Cell Commun Signal       Date:  2011-05-14       Impact factor: 5.712

6.  Dielectrophoretic capture and genetic analysis of single neuroblastoma tumor cells.

Authors:  Erica L Carpenter; JulieAnn Rader; Jacob Ruden; Eric F Rappaport; Kristen N Hunter; Paul L Hallberg; Kate Krytska; Peter J O'Dwyer; Yael P Mosse
Journal:  Front Oncol       Date:  2014-07-31       Impact factor: 6.244

7.  Targeting tumor-associated carbohydrate antigens: a phase I study of a carbohydrate mimetic-peptide vaccine in stage IV breast cancer subjects.

Authors:  Laura F Hutchins; Issam Makhoul; Peter D Emanuel; Angela Pennisi; Eric R Siegel; Fariba Jousheghany; Xueyan Guo; Anastas D Pashov; Behjatolah Monzavi-Karbassi; Thomas Kieber-Emmons
Journal:  Oncotarget       Date:  2017-10-23

8.  GD2 expression in breast cancer.

Authors:  Giulia Orsi; Monica Barbolini; Guido Ficarra; Giovanni Tazzioli; Paola Manni; Tiziana Petrachi; Ilenia Mastrolia; Enrico Orvieto; Carlotta Spano; Malvina Prapa; Shaniko Kaleci; Roberto D'Amico; Valentina Guarneri; Maria Vittoria Dieci; Stefano Cascinu; Pierfranco Conte; Federico Piacentini; Massimo Dominici
Journal:  Oncotarget       Date:  2017-05-09

9.  Using a combination of gangliosides and cell surface vimentin as surface biomarkers for isolating osteosarcoma cells in microfluidic devices.

Authors:  Henrietta O Fasanya; Pablo J Dopico; Zachary Yeager; Z Hugh Fan; Dietmar W Siemann
Journal:  J Bone Oncol       Date:  2021-03-24       Impact factor: 4.491

10.  Mesenchymal stem cells as all-round supporters in a normal and neoplastic microenvironment.

Authors:  Ralf Hass; Anna Otte
Journal:  Cell Commun Signal       Date:  2012-09-03       Impact factor: 5.712

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.